Roche Diabetes Care announce a 25% price drop for Accu-Chek Performa Nano blood glucose monitoring strips
- Reduced price recognises the increasing financial pressures faced by the NHS and helps people with diabetes to access the effective support they need to live healthy lives
- NHS England to conclude its consultation on whether Clinical Commissioning Groups (CCGs) should restrict the prescription of blood glucose testing strips on 28th February 2019
- Roche supports new guidance on best practice for updating formularies for self-monitoring blood glucose testing devices
Today, Roche Diabetes Care announced that the price of Accu-Chek Performa Nano blood glucose test strips will be reduced from £9.95 to £7.50 on the NHS Drug Tariff. This price reduction will make it easier for the NHS to offer people with diabetes the choice of trusted Accu-Chek test strips. The announcement comes before NHS England concludes its consultation on whether CCGs should restrict the prescription of glucose testing strips for people with type 2 diabetes.
Commenting on the announcement Debbie Graham, Head of Blood Glucose Monitoring of Roche said:
“Many people living with diabetes are concerned that the NHS England consultation could result in restricted choice of testing strips. We also recognise the significant burden of diabetes on NHS resources and hope that the savings made from the reduced price for Accu-Chek Performa Nano test strips can unlock investments into technologies that support enhanced self-management for those with all diabetes types, which can ultimately reduce the impact and cost of diabetes-related complications.”
The Roche Diabetes Care portfolio of blood glucose monitors also includes the strip-free Accu-Chek Mobile and the Accu-Chek Aviva Expert, which is the only blood glucose monitor in the UK market with a clinically proven on-board bolus advisor for the benefit of those who carb-count. Defined patient cohorts can benefit from the differentiated features offered by these advanced technologies.1,2
Debbie Graham added:
“When deciding on which blood glucose testing strips to make available in the local health economy, best practice is for decision makers to work with both clinicians and people with diabetes to define the sub-groups of patients who will benefit from the additional features available in some devices.”
With around 4.6 million people living currently with diabetes in the UK and 700 new diagnoses every day, diabetes accounts for a huge 10% of the entire NHS budget – equivalent to £10 billion per year. The cost of treating the complications of diabetes accounts for 80% of the annual budget for diabetes. Ensuring access to, and choice from a range of technologies, as well as effective education and information offerings can help people with diabetes spend more time in range and live well for longer.
Despite significant evidence for the benefits of structured testing, one in four people living with diabetes currently face restrictions in obtaining testing strips3. High frequency testers often find they can access an insufficient quantity of strips on prescription whilst many people with type 2 diabetes are forced to forego blood glucose monitoring or to self-pay.
- Hommel E, Schmidt S, Vistisen D, Neergaard K, Gribhild M, Almdal T, et al. Effects of advanced carbohydrate counting guided by an automated bolus calculator in Type 1 diabetes mellitus (StenoABC): a 12-month, randomized clinical trial. Diabet Med. 2017;34(5):708-15.
- Maran A, Tschoepe D, Di Mauro M, Fisher WA, Loeffler K, Vesper I, et al. Use of an integrated strip-free blood glucose monitoring system increases frequency of self-monitoring and improves glycemic control: Results from the ExAct study. Journal of Clinical & Translational Endocrinology. 2014;1(4):161-6.
- Diabetes UK, Testing Times Report April 2017. Accessed